Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to evaluate the safety and efficacy of Pomalidomide and Dexamethasone
in patients who did not achieve a complete response after initial treatment with both an
alkylating agent (Melphalan or Cyclophosphamide) and Bortezomib. Patients who received 1
previous treatment without achieving a complete response (CR), but who could not be treated
with alkylators and/or Bortezomib due to contraindications, will be included.